RHHBF - Roche slips after in-line Q3 sales
2023-10-19 07:26:46 ET
More on Roche
- Roche: Positive Readouts From Pipeline
- Roche: 2023 Should Mark The Bottom
- Roche: FX Drug But Positive Outlook
- Roche in pact with Monte Rosa to develop cancer and neuro drugs
- Data shows Genentech's Fenebrutinib reduces brain lesions in people with relapsing MS
For further details see:
Roche slips after in-line Q3 sales